Диссертация (1174213), страница 42
Текст из файла (страница 42)
– Р.28. doi: 10.1186/1471-2261-13-28.166. Dlott JS. National assessment of warfarin anticoagulation therapy forstroke prevention in atrial fibrillation /Dlott JS, George RA, Huang X, Odeh M,Kaufman HW, Ansell J, Hylek EM // Circulation. – 2014. - №129(13). – Р.140714.167. Du X.
Risks of cardiovascular events and effects of routine bloodpressure lowering among patients with type 2 diabetes and atrial fibrillation:results of the ADVANCE study /Du X, Ninomiya T, de Galan B, Abadir E,Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, LipGY, Patel A // Eur Heart J.
– 2009. - №30. – Р.1128–1135.168. Eikelboom JW. Dabigatran versus warfarin in patients with mechanicalheart valves / Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB,Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, HarperR, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van deWerf F, REALIGN Investigators // N Engl J Med. – 2013.
- №369. – Р.1206–1214.169. Eraker SA. Understanding and improving patient’s compliance/Eraker SA, Kirscht JP, Becker MH // Ann Int Med. – 1984. - №100. – Р. 258–68.170. Esler M. SPRINT, or false start, towards a lower universal treatedblood pressure target in hypertension /Esler M // Hypertension. –2016. - №67(2). –Р.266-7. pii: HYPERTENSIONAHA.115.06735.171.
European Stroke organization / Guidelines for Management ofIschemic Stroke and Transient Ischaemic Attack // - 2008. - P. 104.172. Fatemi O. Impact of intensive glycemic control on the incidence ofatrial fibrillation and associated cardiovascular outcomes in patients with type 2diabetes mellitus (from the Action to Control Cardiovascular Risk in DiabetesStudy) /Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J,Bigger T, CushmanW, Goff D, Soliman EZ, Thomas A, Papademetriou V // Am JCardiol. – 2014. - №114.
– Р.1217–1222.173. Fox KAA. Improved risk stratification of patients with atrialfibrillation: an integrated GARFIELD-AF tool for the prediction of mortality,stroke and bleed in patients with and without anticoagulation/Fox KAA, Lucas JE, Pieper KS for the GARFIELD-AF Investigators, et al //BMJ Open. – 2017. - №7. – Р.e017157.174. Friberg L.
Balancing stroke and bleeding risks in patients with atrialfibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study /FribergL, Benson L, Lip GY //Eur Heart J. – 2014. - №36. – Р.297–306.175. Friberg L. Assessment of female sex as a risk factor in atrial fibrillationin Sweden: nationwide retrospective cohort study /Friberg L, Benson L,Rosenqvist M, Lip GY // BMJ. – 2012.
- №344. – Р. e3522.252176. Friberg L. Stroke in paroxysmal atrial fibrillation: report from theStockholm Cohort of Atrial Fibrillation /Friberg L, Hammar N, Rosenqvist M //Eur Heart J. – 2010. - №31. – Р.967–975. doi: 10.1093/eurheartj/ehn599.177. Friberg L. Evaluation of risk stratification schemes for is-chaemicstroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish AtrialFibrillation Cohort study /Friberg L, Rosenqvist M, Lip GY // Eur Heart J. – 2012.- № 33. – Р. 1500–1510.178.
Friberg L. Benefit of Anticoagulation Unlikely in Patients With AtrialFibrillation and a CHA2DS2-VASc Score of 1 /Friberg L, Skeppholm M, Terént A// J Am Coll Cardiol. – 2015. - №65(3). Р.225-32. doi: 10.1016/j.jacc.2014.10.052.179. Gaita F. Prevalence of silent cerebral ischemia in paroxysmal andpersistent atrial fibrillation and correlation with cognitive function /Gaita F,Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, Bergamasco L,Boffano C, Valentini MC, Cesarani F, Scaglione M // J Am Coll Cardiol. – 2013. №62(21). – Р.1990-7. doi: 10.1016/j.jacc.2013.05.074.180.
Gallego P. SAMe-TT2R2 score, time in therapeutic range, andoutcomes in anticoagulated patients with atrial fibrillation /Gallego P, Roldan V,Marin F, Galvez J, Valdes M, Vicente V, Lip GY // Am J Med. – 2014. - №127. –р.1083–1088.181. Glader EL. Large variations in the use of oral anticoagulants in strokepatients with atrial fibrillation: a Swedish national perspective /Glader EL,Stegmayr B, Norrving B, Terént A, Hulter-Asberg K, Wester PO, Asplund K;Riks-Stroke Collaboration // J Intern Med.
– 2004. -№ 255(1). – Р.22-32.182. Glynn LG. Interventions used to improve control of blood pressure inpatients with hypertension /Glynn LG, Murphy AW, Smith SM, Schroeder K,Fahey T // Cochrane Database Syst Rev. - 2010. - №17;(3). Р.CD005182.183. Go AS. Impact of proteinuria and glomerular filtration rate on risk ofthromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrialfibrillation (ATRIA) study /Go AS, Fang MC, Udaltsova N et al.// Circulation.
2009. - Vol. 119 (10). - P. 1363–1369184. Go AS. Prevalence of diagnosed atrial fibrillation in adults: nationalimplications for rhythm management and stroke prevention: the AnTicoagulationand Risk Factors in Atrial Fibrillation (ATRIA) Study /Go AS, Hylek EM, PhillipsKA, et al. // JAMA. – 2001. - №285. – Р.2370–2375.185. Goette A. Acute atrial tachyarrhythmia induces angiotensin II type 1receptor-mediated oxidative stress and microvascular flow abnormalities in theventricles /Goette A, Bukowska A, Dobrev D, et al. // Eur Heart J. – 2009.
- №30. Р. 1411–1420.186. González Pacheco H. Patients with hypertensive crises who areadmitted to a coronary care unit: clinical characteristics and outcomes /GonzálezPacheco H, Morales Victorino N, Núñez Urquiza JP, Altamirano Castillo A, JuárezHerrera U, Arias Mendoza A, Azar Manzur F, Briseño de la Cruz JL, MartínezSánchez C //J Clin Hypertens (Greenwich). - 2013. - №15(3). - Р. 210-214.253187. Goodfellow JA. Management of blood pressure in acute stroke/Goodfellow JA, Dawson J, Quinn TJ // Expert Rev Neurother. – 2013.
- №13(8).- Р. 911-923.188. Gorst-Rasmussen A. Dabigatran adherence in atrial fibrillation patientsduring the first year after diagnosis: a nationwide cohort study /Gorst-RasmussenA, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA // J Thromb Haemost.– 2015. - №13. Р.495–504.189.
Gradman AH. Optimal blood pressure targets in older adults. How lowis low enough? /Gradman AH // J AmColl Cardiol. - 2014. - Vol. 64. - P.794–796.190. Graham DJ. Cardiovascular, bleeding, and mortality risks in elderlyMedicare patients treated with dabigatran or warfarin for nonvalvular atrialfibrillation /Graham DJ, Reichman ME,Wernecke M, Zhang R, Southworth MR,Levenson M et al. // Circulation. – 2015. - №131. Р.157–64.191. Granger CB. Apixaban versus warfarin in patients with atrialfibrillation /Granger CB, Alexander JH, McMurray JJ et al., for the ARISTOTLECommittees and Investigators // N Engl J Med.
– 2011. -№ 365. – Р. 981-992.192. Gruesser M. Structured patient education for out-patients withhypertension in general practice: a model project in Germany/Gruesser M,Hartmann P, Schlottmann N, Lohmann FW, Sawicki PT, Joergens V// J HumHypertens. – 1997. - № 11 (8). Р. 501–6.193. Ha AC. Oral Anticoagulation for Stroke Prevention in CanadianPractice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation(SPRINT-AF) Registry /Ha AC, Singh N, Cox JL, Mancini GB, Dorian P,Fournier C, Gladstone DJ, Lockwood E, Shuaib A, Kajil M, Tsigoulis M, GuptaMK // Can J Cardiol.
– 2016. - №32(2). Р.204-10.194. Haas S. Quality of Vitamin K Antagonist Control and 1-YearOutcomes in Patients with Atrial Fibrillation: A Global Perspective from theGARFIELD-AF Registry / Haas S, Ten Cate H, Accetta G, Angchaisuksiri P,Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ,Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, SchellongSM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AFInvestigators // PLoS One.
– 2016. - №11(10). Р.e0164076.195. Hackman DG. Combining multiple approaches for the secondaryprevention of vascular events after stroke. A quantitative modeling study/Hackman DG, Spence JD // Stroke. - 2007. - Vol. 38. - P.1881–1885.196. Harel Z. Warfarin and the Risk of Stroke and Bleeding in PatientsWith Atrial Fibrillation Receiving Dialysis: A Systematic Review and Metaanalysis /Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, Saposnik G,Sood MM, Molnar AO, Perl J, Wald RM, Silver S, Wald R //Can J Cardiol.
–2017. - №33(6). – Р.737-746. doi:10.1016/j.cjca.2017.02.004.197. Hart RG. Stroke prevention in atrial fibrillation patients with chronickidney disease /Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ// Can J Cardiol. – 2013. - №29. – Р.S71–78.254198. Hart RG. Which Patients With Atrial Fibrillation and Chronic KidneyDisease Should Receive Anticoagulation-And With Which Anticoagulant? /HartRG, Ingram AJ, Eikelboom JW // Can J Cardiol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
